A subset of patients with stage III colon cancer when treated with irinotecan-based therapy had improved survival rates. This is according to a new study in emGastroenterology/emsup1/sup, the official journal of the American Gastroenterological Association. When added to the standard chemotherapy treatment - fluorouracil and leucovorin - adjuvant irinotecan therapy improved overall survival rates for patients with the CpG island methylator phenotype ...
Read MoreYou have just read an article categorized health
titled Drug Shows Promise for Subset of Patients With Stage III Colon Cancer.
Written by:
editor - Sunday, August 31, 2014
There are currently no comments for "Drug Shows Promise for Subset of Patients With Stage III Colon Cancer"
Post a Comment